Blockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugs
The experimental weight-loss drug is a triple agonist and the first of its kind to reach a phase 3 clinical trial
The experimental weight-loss drug is a triple agonist and the first of its kind to reach a phase 3 clinical trial
What's Your Reaction?
SIN
ScienceX Information Network (SIN) | ScienceX Innovations
